IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishBackground: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. Methods: We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients' clinical outcome. Results: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). Conclusions: Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment.
Martini, M., De Pascalis, I., D'alessandris, Q. G., Fiorentino, V., Pierconti, F., Marei, H. E., Ricci-vitiani, L., Pallini, R., Larocca, L. M., VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma, <<BMC CANCER>>, 2018; 18 (1): 553-559. [doi:10.1186/s12885-018-4442-2] [http://hdl.handle.net/10807/119662]
| Autori: | ||
| Titolo: | VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1186/s12885-018-4442-2 | |
| URL: | http://www.biomedcentral.com/bmccancer/ | |
| Data di pubblicazione: | 2018 | |
| Abstract: | Background: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab available to target the heavier isoforms of VEGF, which are the most clinically relevant. Methods: We assessed the plasma level of VEGF-121 in a brain xenograft model, in human healthy controls, and in patients suffering from recurrent GB before and after bevacizumab treatment. Data were matched with patients' clinical outcome. Results: In athymic rats with U87MG brain xenografts, the level of plasma VEGF-121 relates with tumor volume and it significantly decreases after iv infusion of bevacizumab. Patients with recurrent GB show higher plasma VEGF-121 than healthy controls (p = 0.0002) and treatment with bevacizumab remarkably reduced the expression of VEGF-121 in plasma of these patients (p = 0.0002). Higher plasma level of VEGF-121 was significantly associated to worse PFS and OS (p = 0.0295 and p = 0.0246, respectively). Conclusions: Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment. | |
| Lingua: | Inglese | |
| Rivista: | ||
| Citazione: | Martini, M., De Pascalis, I., D'alessandris, Q. G., Fiorentino, V., Pierconti, F., Marei, H. E., Ricci-vitiani, L., Pallini, R., Larocca, L. M., VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma, <<BMC CANCER>>, 2018; 18 (1): 553-559. [doi:10.1186/s12885-018-4442-2] [http://hdl.handle.net/10807/119662] | |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
Copyright © 2021